Preimplantation Genetic Testing Market Forecasts to 2032 – Global Analysis By Product (Reagents & Consumables, Instruments and Software), Procedure, Technology, Application, End User and By Geography
Description
According to Stratistics MRC, the Global Preimplantation Genetic Testing Market is accounted for $883.1 million in 2025 and is expected to reach $2103.3 million by 2032 growing at a CAGR of 13.2% during the forecast period. Preimplantation genetic testing is a laboratory procedure performed on embryos created via in vitro fertilization (IVF) to identify genetic or chromosomal abnormalities before pregnancy. It involves analyzing one or more cells from the embryo to screen for inherited diseases, chromosomal normality, or other genetic conditions. This testing helps select healthy embryos for implantation, reducing the risk of genetic disorders in the offspring.
According to the U.S. Department of Health and Human Services, infertility affects millions of Americans at some point in their lives. IVF is a crucial fertility treatment, accounting for over 99% of ART procedures.
Market Dynamics:
Driver:
Increasing incidence of genetic disorders and infertility
The rising global prevalence of genetic disorders and infertility is a primary driver for the preimplantation genetic testing market. Couples opting for assisted reproductive technologies increasingly seek genetic screening to reduce the risk of inherited conditions in embryos. Advancements in diagnostic accuracy and awareness of chromosomal abnormalities have further spurred demand. With maternal age on the rise and infertility rates escalating, particularly in urban populations, PGT is emerging as a proactive solution to ensure healthy pregnancies.
Restraint:
High cost and limited reimbursement policies
Despite its clinical benefits, the high cost of preimplantation genetic testing remains a significant barrier, especially in developing economies. Limited insurance coverage and restrictive reimbursement policies discourage widespread adoption. Many patients are burdened with out-of-pocket expenses, particularly when PGT is bundled with in-vitro fertilization. Moreover, variability in regulatory frameworks across regions further constrains access. These financial and policy constraints hinder market penetration, particularly among middle-income demographics and public healthcare systems.
Opportunity:
Growing adoption of IVF and assisted reproductive technologies
Widespread adoption of in-vitro fertilization (IVF) and other assisted reproductive technologies (ART) presents a strong growth opportunity for the PGT market. As success rates of IVF improve, clinics increasingly integrate genetic testing to enhance implantation outcomes and reduce miscarriages. Rising acceptance of ART among same-sex couples, single parents, and those with recurrent pregnancy loss has broadened the patient base. The integration of AI and next-generation sequencing (NGS) further enhances PGT accuracy, attracting newer demographics and boosting clinical success.
Threat:
Lack of awareness in certain populations
Inadequate awareness regarding preimplantation genetic testing, particularly in rural and underdeveloped regions, poses a critical threat to market expansion. Misconceptions, socio-cultural taboos, and limited genetic literacy reduce adoption rates despite increasing infertility cases. Additionally, lack of education among patients and healthcare providers about the benefits and eligibility criteria of PGT hinders early consultation. This awareness gap continues to delay timely intervention, particularly among high-risk carriers of genetic diseases, curbing the market’s full potential.
Covid-19 Impact
The COVID-19 pandemic disrupted fertility services globally, leading to postponed IVF cycles and a temporary decline in PGT procedures. Clinics faced staff shortages, mobility restrictions, and supply chain interruptions for reagents and test kits. However, post-pandemic recovery has been marked by a rebound in fertility treatments and increased emphasis on genetic health. Telemedicine, digitized consultations, and remote genetic counseling have helped restore patient engagement, supporting renewed growth in PGT services amid strengthened healthcare digitization.
The reagents & consumables segment is expected to be the largest during the forecast period
The reagents & consumables segment is expected to account for the largest market share during the forecast period, due to its recurring demand across every testing cycle. Laboratories rely on high-quality reagents, probes, and kits for accurate embryo analysis, driving consistent consumption. Continuous advancements in molecular diagnostic tools and NGS-based testing have also increased demand for specialized reagents. Additionally, the growing volume of IVF procedures globally necessitates regular procurement of consumables, making this segment a critical revenue driver for diagnostic suppliers.
The preimplantation genetic screening segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the preimplantation genetic screening segment is predicted to witness the highest growth rate, impelled by the growing desire to improve IVF success rates and prevent chromosomal abnormalities. PGS aids in identifying aneuploidy and structural rearrangements, enabling the selection of genetically viable embryos. As maternal age rises, especially in developed nations, the relevance of PGS continues to grow. Additionally, the integration of NGS and automated analytics is enhancing efficiency, accuracy, and accessibility of screening protocols.
Region with largest share:
During the forecast period, the Asia Pacific region is expected to hold the largest market share, driven by expanding fertility tourism, rising infertility rates, and increased ART adoption. Countries like India, China, and Japan are witnessing a surge in advanced reproductive services, backed by improving healthcare infrastructure and supportive policies. In addition, growing medical tourism and competitive treatment costs attract international patients. The region's large reproductive-age population and rising awareness around genetic health contribute to its dominant market position.
Region with highest CAGR:
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR attributed to advanced healthcare infrastructure, high adoption of ART, and favorable reimbursement scenarios in select states. Strong demand for personalized reproductive solutions and early screening among older parents bolsters PGT uptake. Furthermore, the presence of leading genomic testing firms, regulatory clarity, and ongoing clinical innovations in embryo diagnostics support rapid market expansion. Patient awareness and fertility education initiatives also enhance regional growth momentum.
Key players in the market
Some of the key players in Preimplantation Genetic Testing Market include Illumina, Inc., Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., CooperSurgical, Abbott Laboratories, Natera, Rubicon Genomics, Oxford Gene Technology, Yikon Genomics, Good Start Genetics, Invicta Genetics, Progenesis, Igenomix, Bioarray S.L., Quest Diagnostics, Fulgent Genetics, Inc., Labcorp, and Genea Limited.
Key Developments:
In February 2025, Thermo Fisher Scientific expanded its PGT capabilities with an integrated NGS workflow allowing a single sample to be assessed for both PGT-A (aneuploidy) and PGT-M (monogenic disorders) using Ion Torrent technology—offering comprehensive results with rapid turnaround and accessible analysis tools.
In January 2025, Illumina launched major upgrades to its NovaSeq X Series, including a new single-flow-cell system, advanced software, and improved reagent kits, further strengthening its leadership in genomic sequencing, a key technology for PGT.
Products Covered:
• Reagents & Consumables
• Instruments
• Software
Procedures Covered:
• Preimplantation Genetic Screening
• Preimplantation Genetic Diagnosis
Technologies Covered:
• Next Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Fluorescent In-Situ Hybridization (FISH)
• Other Technologies
Applications Covered:
• Chromosomal Abnormalities
• X-linked Diseases
• Embryo Testing
• Aneuploidy Screening
• HLA Typing
• Other Applications
End Users Covered:
• Fertility Centers
• Hospitals
• Diagnostic Centers
• Research Centers & Academic Labs
Regions Covered:
• North America US Canada Mexico
• Europe Germany UK Italy France Spain Rest of Europe
• Asia Pacific Japan China India Australia New Zealand South KoreaRest of Asia Pacific
• South America Argentina Brazil Chile Rest of South America
• Middle East & Africa Saudi Arabia UAE Qatar South Africa Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
According to the U.S. Department of Health and Human Services, infertility affects millions of Americans at some point in their lives. IVF is a crucial fertility treatment, accounting for over 99% of ART procedures.
Market Dynamics:
Driver:
Increasing incidence of genetic disorders and infertility
The rising global prevalence of genetic disorders and infertility is a primary driver for the preimplantation genetic testing market. Couples opting for assisted reproductive technologies increasingly seek genetic screening to reduce the risk of inherited conditions in embryos. Advancements in diagnostic accuracy and awareness of chromosomal abnormalities have further spurred demand. With maternal age on the rise and infertility rates escalating, particularly in urban populations, PGT is emerging as a proactive solution to ensure healthy pregnancies.
Restraint:
High cost and limited reimbursement policies
Despite its clinical benefits, the high cost of preimplantation genetic testing remains a significant barrier, especially in developing economies. Limited insurance coverage and restrictive reimbursement policies discourage widespread adoption. Many patients are burdened with out-of-pocket expenses, particularly when PGT is bundled with in-vitro fertilization. Moreover, variability in regulatory frameworks across regions further constrains access. These financial and policy constraints hinder market penetration, particularly among middle-income demographics and public healthcare systems.
Opportunity:
Growing adoption of IVF and assisted reproductive technologies
Widespread adoption of in-vitro fertilization (IVF) and other assisted reproductive technologies (ART) presents a strong growth opportunity for the PGT market. As success rates of IVF improve, clinics increasingly integrate genetic testing to enhance implantation outcomes and reduce miscarriages. Rising acceptance of ART among same-sex couples, single parents, and those with recurrent pregnancy loss has broadened the patient base. The integration of AI and next-generation sequencing (NGS) further enhances PGT accuracy, attracting newer demographics and boosting clinical success.
Threat:
Lack of awareness in certain populations
Inadequate awareness regarding preimplantation genetic testing, particularly in rural and underdeveloped regions, poses a critical threat to market expansion. Misconceptions, socio-cultural taboos, and limited genetic literacy reduce adoption rates despite increasing infertility cases. Additionally, lack of education among patients and healthcare providers about the benefits and eligibility criteria of PGT hinders early consultation. This awareness gap continues to delay timely intervention, particularly among high-risk carriers of genetic diseases, curbing the market’s full potential.
Covid-19 Impact
The COVID-19 pandemic disrupted fertility services globally, leading to postponed IVF cycles and a temporary decline in PGT procedures. Clinics faced staff shortages, mobility restrictions, and supply chain interruptions for reagents and test kits. However, post-pandemic recovery has been marked by a rebound in fertility treatments and increased emphasis on genetic health. Telemedicine, digitized consultations, and remote genetic counseling have helped restore patient engagement, supporting renewed growth in PGT services amid strengthened healthcare digitization.
The reagents & consumables segment is expected to be the largest during the forecast period
The reagents & consumables segment is expected to account for the largest market share during the forecast period, due to its recurring demand across every testing cycle. Laboratories rely on high-quality reagents, probes, and kits for accurate embryo analysis, driving consistent consumption. Continuous advancements in molecular diagnostic tools and NGS-based testing have also increased demand for specialized reagents. Additionally, the growing volume of IVF procedures globally necessitates regular procurement of consumables, making this segment a critical revenue driver for diagnostic suppliers.
The preimplantation genetic screening segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the preimplantation genetic screening segment is predicted to witness the highest growth rate, impelled by the growing desire to improve IVF success rates and prevent chromosomal abnormalities. PGS aids in identifying aneuploidy and structural rearrangements, enabling the selection of genetically viable embryos. As maternal age rises, especially in developed nations, the relevance of PGS continues to grow. Additionally, the integration of NGS and automated analytics is enhancing efficiency, accuracy, and accessibility of screening protocols.
Region with largest share:
During the forecast period, the Asia Pacific region is expected to hold the largest market share, driven by expanding fertility tourism, rising infertility rates, and increased ART adoption. Countries like India, China, and Japan are witnessing a surge in advanced reproductive services, backed by improving healthcare infrastructure and supportive policies. In addition, growing medical tourism and competitive treatment costs attract international patients. The region's large reproductive-age population and rising awareness around genetic health contribute to its dominant market position.
Region with highest CAGR:
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR attributed to advanced healthcare infrastructure, high adoption of ART, and favorable reimbursement scenarios in select states. Strong demand for personalized reproductive solutions and early screening among older parents bolsters PGT uptake. Furthermore, the presence of leading genomic testing firms, regulatory clarity, and ongoing clinical innovations in embryo diagnostics support rapid market expansion. Patient awareness and fertility education initiatives also enhance regional growth momentum.
Key players in the market
Some of the key players in Preimplantation Genetic Testing Market include Illumina, Inc., Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., CooperSurgical, Abbott Laboratories, Natera, Rubicon Genomics, Oxford Gene Technology, Yikon Genomics, Good Start Genetics, Invicta Genetics, Progenesis, Igenomix, Bioarray S.L., Quest Diagnostics, Fulgent Genetics, Inc., Labcorp, and Genea Limited.
Key Developments:
In February 2025, Thermo Fisher Scientific expanded its PGT capabilities with an integrated NGS workflow allowing a single sample to be assessed for both PGT-A (aneuploidy) and PGT-M (monogenic disorders) using Ion Torrent technology—offering comprehensive results with rapid turnaround and accessible analysis tools.
In January 2025, Illumina launched major upgrades to its NovaSeq X Series, including a new single-flow-cell system, advanced software, and improved reagent kits, further strengthening its leadership in genomic sequencing, a key technology for PGT.
Products Covered:
• Reagents & Consumables
• Instruments
• Software
Procedures Covered:
• Preimplantation Genetic Screening
• Preimplantation Genetic Diagnosis
Technologies Covered:
• Next Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Fluorescent In-Situ Hybridization (FISH)
• Other Technologies
Applications Covered:
• Chromosomal Abnormalities
• X-linked Diseases
• Embryo Testing
• Aneuploidy Screening
• HLA Typing
• Other Applications
End Users Covered:
• Fertility Centers
• Hospitals
• Diagnostic Centers
• Research Centers & Academic Labs
Regions Covered:
• North America US Canada Mexico
• Europe Germany UK Italy France Spain Rest of Europe
• Asia Pacific Japan China India Australia New Zealand South KoreaRest of Asia Pacific
• South America Argentina Brazil Chile Rest of South America
• Middle East & Africa Saudi Arabia UAE Qatar South Africa Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Table of Contents
200 Pages
- 1 Executive Summary
- 2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
- 3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Product Analysis
- 3.7 Technology Analysis
- 3.8 Application Analysis
- 3.9 End User Analysis
- 3.10 Emerging Markets
- 3.11 Impact of Covid-19
- 4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
- 5 Global Preimplantation Genetic Testing Market, By Product
- 5.1 Introduction
- 5.2 Reagents & Consumables
- 5.3 Instruments
- 5.4 Software
- 6 Global Preimplantation Genetic Testing Market, By Procedure
- 6.1 Introduction
- 6.2 Preimplantation Genetic Screening
- 6.3 Preimplantation Genetic Diagnosis
- 7 Global Preimplantation Genetic Testing Market, By Technology
- 7.1 Introduction
- 7.2 Next Generation Sequencing (NGS)
- 7.3 Polymerase Chain Reaction (PCR)
- 7.4 Fluorescent In-Situ Hybridization (FISH)
- 7.5 Other Technologies
- 8 Global Preimplantation Genetic Testing Market, By Application
- 8.1 Introduction
- 8.2 Chromosomal Abnormalities
- 8.3 X-linked Diseases
- 8.4 Embryo Testing
- 8.5 Aneuploidy Screening
- 8.6 HLA Typing
- 8.7 Other Applications
- 9 Global Preimplantation Genetic Testing Market, By End User
- 9.1 Introduction
- 9.2 Fertility Centers
- 9.3 Hospitals
- 9.4 Diagnostic Centers
- 9.5 Research Centers & Academic Labs
- 10 Global Preimplantation Genetic Testing Market, By Geography
- 10.1 Introduction
- 10.2 North America
- 10.2.1 US
- 10.2.2 Canada
- 10.2.3 Mexico
- 10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 Italy
- 10.3.4 France
- 10.3.5 Spain
- 10.3.6 Rest of Europe
- 10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 New Zealand
- 10.4.6 South Korea
- 10.4.7 Rest of Asia Pacific
- 10.5 South America
- 10.5.1 Argentina
- 10.5.2 Brazil
- 10.5.3 Chile
- 10.5.4 Rest of South America
- 10.6 Middle East & Africa
- 10.6.1 Saudi Arabia
- 10.6.2 UAE
- 10.6.3 Qatar
- 10.6.4 South Africa
- 10.6.5 Rest of Middle East & Africa
- 11 Key Developments
- 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 11.2 Acquisitions & Mergers
- 11.3 New Product Launch
- 11.4 Expansions
- 11.5 Other Key Strategies
- 12 Company Profiling
- 12.1 Illumina, Inc.
- 12.2 Thermo Fisher Scientific, Inc.
- 12.3 Agilent Technologies, Inc.
- 12.4 PerkinElmer, Inc.
- 12.5 CooperSurgical
- 12.6 Abbott Laboratories
- 12.7 Natera
- 12.8 Rubicon Genomics
- 12.9 Oxford Gene Technology
- 12.10 Yikon Genomics
- 12.11 Good Start Genetics
- 12.12 Invicta Genetics
- 12.13 Progenesis
- 12.14 Igenomix
- 12.15 Bioarray S.L.
- 12.16 Quest Diagnostics
- 12.17 Fulgent Genetics, Inc.
- 12.18 Labcorp
- 12.19 Genea Limited
- List of Tables
- Table 1 Global Preimplantation Genetic Testing Market Outlook, By Region (2024-2032) ($MN)
- Table 2 Global Preimplantation Genetic Testing Market Outlook, By Product (2024-2032) ($MN)
- Table 3 Global Preimplantation Genetic Testing Market Outlook, By Reagents & Consumables (2024-2032) ($MN)
- Table 4 Global Preimplantation Genetic Testing Market Outlook, By Instruments (2024-2032) ($MN)
- Table 5 Global Preimplantation Genetic Testing Market Outlook, By Software (2024-2032) ($MN)
- Table 6 Global Preimplantation Genetic Testing Market Outlook, By Procedure (2024-2032) ($MN)
- Table 7 Global Preimplantation Genetic Testing Market Outlook, By Preimplantation Genetic Screening (2024-2032) ($MN)
- Table 8 Global Preimplantation Genetic Testing Market Outlook, By Preimplantation Genetic Diagnosis (2024-2032) ($MN)
- Table 9 Global Preimplantation Genetic Testing Market Outlook, By Technology (2024-2032) ($MN)
- Table 10 Global Preimplantation Genetic Testing Market Outlook, By Next Generation Sequencing (NGS) (2024-2032) ($MN)
- Table 11 Global Preimplantation Genetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
- Table 12 Global Preimplantation Genetic Testing Market Outlook, By Fluorescent In-Situ Hybridization (FISH) (2024-2032) ($MN)
- Table 13 Global Preimplantation Genetic Testing Market Outlook, By Other Technologies (2024-2032) ($MN)
- Table 14 Global Preimplantation Genetic Testing Market Outlook, By Application (2024-2032) ($MN)
- Table 15 Global Preimplantation Genetic Testing Market Outlook, By Chromosomal Abnormalities (2024-2032) ($MN)
- Table 16 Global Preimplantation Genetic Testing Market Outlook, By X-linked Diseases (2024-2032) ($MN)
- Table 17 Global Preimplantation Genetic Testing Market Outlook, By Embryo Testing (2024-2032) ($MN)
- Table 18 Global Preimplantation Genetic Testing Market Outlook, By Aneuploidy Screening (2024-2032) ($MN)
- Table 19 Global Preimplantation Genetic Testing Market Outlook, By HLA Typing (2024-2032) ($MN)
- Table 20 Global Preimplantation Genetic Testing Market Outlook, By Other Applications (2024-2032) ($MN)
- Table 21 Global Preimplantation Genetic Testing Market Outlook, By End User (2024-2032) ($MN)
- Table 22 Global Preimplantation Genetic Testing Market Outlook, By Fertility Centers (2024-2032) ($MN)
- Table 23 Global Preimplantation Genetic Testing Market Outlook, By Hospitals (2024-2032) ($MN)
- Table 24 Global Preimplantation Genetic Testing Market Outlook, By Diagnostic Centers (2024-2032) ($MN)
- Table 25 Global Preimplantation Genetic Testing Market Outlook, By Research Centers & Academic Labs (2024-2032) ($MN)
- Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
